http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#Head http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#provenance http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#pubinfo http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion http://purl.obolibrary.org/obo/DOID_5844 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5844 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00669 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association http://www.w3.org/2000/01/rdf-schema#label "Sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease (see WARNINGS). Because sumatriptan succinate tablets may increase blood pressure, they should not be given to patients with uncontrolled hypertension. Concurrent administration of MAO-A inhibitors or use within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated (see CLINICAL PHARMACOLOGY, Drug Interactions and PRECAUTIONS, Drug Interactions). Sumatriptan succinate tablets should not be administered to patients with hemiplegic or basilar migraine. Sumatriptan succinate tablets and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should sumatriptan succinate tablets and another 5-HT 1 Sumatriptan succinate tablets are contraindicated in patients with hypersensitivity to sumatriptan or any of their components. Sumatriptan succinate tablets are contraindicated in patients with severe hepatic impairment." http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00669 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#provenance http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#pubinfo http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig http://purl.org/nanopub/x/hasSignature MCCHwl2Tu+vZ30xzQTJam/hrgHuIma81K6HHEqJiralarr+T8c6OqCADOG4Ay7vIueCdl3looLcr0giti4YtJ45RzWzSOhYrWrGSoDgJqu6uyY4wR/wUPss4IGtIl2QBGngm1mVC0DoXHYg6ckvEJ8fr5aPYriyqTJG4k7mWaQk= http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://purl.org/dc/terms/created 2021-08-23T13:07:23.811+02:00 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAvsTcZdwONezc2C34GHPP5z427RMeatB7Pqb-EjABbC0 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY